With two years of experience selling Alzheimer’s disease antibody Leqembi so far under Eisai’s belt, the Japanese drugmaker ...

There are glimmers of hope, however, with Eisai reporting last month that it is on track to meet that fiscal 2024 sales ...

The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive ...

The European Union's drugs regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's small impact on ...

Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...

The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of ...

The European Medicines Agency committee declined to approve Eli Lilly's Alzheimer’s treatment, citing risks of brain bleeding ...

According to Eisai's simulation, Leqembi sales will reach JPY 250 to 280 billion for their financial year (FY) 2027, which ends in March 2028. Eisai's presentation can be found on https://www ...

After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease ...

BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi. According to Eisai's simulation, Leqembi ...